Trial Profile
A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary)
- Indications Hearing loss
- Focus Therapeutic Use
- 28 Apr 2022 Status changed from active, no longer recruiting to completed.
- 07 Mar 2022 Planned End Date changed from 1 Jan 2022 to 1 Dec 2022.
- 07 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2022.